Sheila Riazi

Since Dr. Riazi’s appointment, the malignant hyperthermia (MH) centre has been revitalized by restarting diagnostic testing (including both caffeine-halothane contracture test (CHCT), and genetic testing). Under Dr. Riazi the centre has also secured funding for new equipment, started research projects and implemented curriculum for MH-elective rotation for anesthesia residents. A new Canadian-based website has raised awareness and specifically increased the number of reported MH cases to the unit. Dr. Riazi’s unit has regained respect in the MH community and she has been selected as member of board of directors, as well as professional advisory committee of MHAUS.